DIRS.INFO The most relevant business & tech news

☆ Moderna, Pfizer say updated COVID shots generate strong response vs newer variant
▼ + stars: | 2023-09-06 | by ( Patrick Wingrove | ) www.reuters.com time to read: +3 min

Moderna said its shot generated an 8.7-fold increase in neutralizing antibodies against BA.2.86 compared with an untreated natural antibody response in clinical trials in humans. Pfizer said its updated vaccine with partner BioNTech (22UAy.DE) elicited a strong antibody response against BA.2.86 in a preclinical study in mice. Moderna, Pfizer/BioNTech and relative newcomer to the COVID vaccine market Novavax (NVAX.O) have created versions of their shots aimed at the XBB.1.5 subvariant, the dominant variant through most of 2023. Moderna shares were down 1.6% and Pfizer shares were off nearly 3% in afternoon trading. The Omicron offshoot carries more than 35 mutations in key portions of the virus compared with XBB.1.5, the target of the updated shots.

Persons: Moderna, Jacqueline Miller, BioNTech, Cowen, Tyler Van Buren, Dado Ruvic, Patrick Wingrove, Michael Erman, Bill Berkrot Organizations: Pfizer, World Health Organization, WHO, U.S . Centers for Disease Control, Prevention, ” Moderna, Moderna, REUTERS, CDC, Omicron, U.S . Food, Drug Administration, Britain's Medicines, Healthcare, Agency, Reuters, Thomson Locations: Switzerland, South Africa, Israel, Denmark, U.S, Britain, New York, New Jersey

☆ TD Cowen downgrades Moderna on uncertain flu, Covid-19 winter vaccine demand
▼ + stars: | 2023-08-04 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

TD Cowen is taking a step back on Moderna . The firm downgraded shares in the vaccine provider to market perform from outperform and lowered its price target to $125 from $145. "We don't yet know where the COVID-19 vaccines business will settle out, and this fall/ winter season will be crucial for determining that," Van Buren said. The analyst added that additional uncertainty over how many vaccine reorders will come to fruition also casts doubt on the firm's $7 billion estimate for annual revenue. MRNA YTD mountain Moderna stock has dipped nearly 40% from the start of the year.

Persons: Cowen, Tyler Van Buren, Van Buren, — CNBC's Michael Bloom Organizations: Moderna Locations: Moderna

☆ BridgeBio's heart disease drug meets late-stage study goal, shares soar
▼ + stars: | 2023-07-17 | by ( Khushi Mandowara | ) www.reuters.com time to read: +2 min

July 17 (Reuters) - BridgeBio Pharma Inc's (BBIO.O) experimental drug for a rare heart disease showed significant improvement in patients in a late-stage study, sending its shares surging 65% on Monday. BridgeBio's drug improved survival by 81% in the study patients compared to 74% on the placebo, and also reduced frequency of heart disease-related hospitalization by 50%. The California-based company also provided additional data comparing it with Pfizer's drug. Acoramidis showed 92% improvement on heart failure test, compared to patients on placebo and Pfizer's drug at 30 months. The additional data suggests that BridgeBio's drug was better than tafamidis in controlling the disease, said TD Cowen analyst Tyler Van Buren.

Persons: acoramidis, Acoramidis, Cowen, Tyler Van, Luca Issi, BridgeBio, BridgeBio's, Khushi, Nivedita Bhattacharjee Organizations: BridgeBio Pharma, Alnylam Pharmaceuticals, Ionis Pharmaceutical, RBC Capital, U.S . Food, Drug Administration, Thomson Locations: U.S, California, Tyler Van Buren, Bengaluru

☆ Moderna shares pop 7% after Cowen upgrades stock, saying it 'will be a leader' in RSV vaccines
▼ + stars: | 2023-03-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Moderna shares jumped by nearly 7% on Wednesday after TD Cowen upgraded the stock, saying the company will "be a leader" in the RSV vaccine market. Cowen pointed to the company's potential RSV vaccine, noting that key opinion leaders believe RSV will be a "three-player vaccine market" between Moderna and drugmakers Pfizer and GSK. Moderna's RSV vaccine performed well in clinical trials and was well tolerated by patients, the note said. Moderna's RSV vaccines for adults ages 60 and older received Breakthrough Therapy Designation from the Food and Drug Administration in late January. Cowen noted that Moderna believes the regulatory support of its competitors' RSV candidates "should read-through" to its own.

☆ Cowen says buy Regeneron, success of drugs could help pharmaceutical stock
▼ + stars: | 2023-01-30 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Regeneron 's stock could get a boost as one of its major drugs gains a competitive edge and another continues dominating, according to Cowen. Analyst Tyler Van Buren on Monday upgraded the pharmaceutical stock to outperform from market perform. Van Buren said Eylea has an "incremental improvement" over competing drug Vabysmo after previously being considered equal. "The HD Eylea data has altered the trajectory of Regeneron," Van Buren said in a note to clients. Van Buren said Regeneron's cancer portfolio continues to post little to no value, but there's potential opportunity in Odronextamab and Fianlimab specifically.

RSV, which produces symptoms similar to a cold but can be fatal for young children and older adults, causes about 14,000 deaths annually in adults ages 65 and older. Moderna, Pfizer Inc (PFE.N) and GSK Plc (GSK.L) are racing to get their RSV vaccines to market first. Pfizer's RSV vaccine was found to be 66.7% effective against two or more symptoms in late-stage trials. "It's very exciting to see progress in RSV vaccines in older adults, and I think both of those vaccines have shown pretty remarkable results as well," Hoge said. The RSV vaccine market could be worth more than $10 billion globally, half of which would come from the United States, according to Cowen analyst Tyler Van Buren.

Search resuls for: "Tyler Van Buren"

6 mentions found